FSH Test: Which Labs to Order Alongside It (and What the Results Mean for You)

What FSH Actually Measures (and Why One Number Is Not Enough)

FSH is a glycoprotein hormone secreted by the anterior pituitary gland. Its job is to signal the ovary to recruit and mature follicles each cycle. When ovarian reserve or ovarian function declines, the pituitary compensates by releasing more FSH, so a rising FSH is the body's attempt to shout louder at aging or damaged ovaries.

The problem is that FSH fluctuates considerably within a single cycle and between cycles. Research published in the journal Fertility and Sterility shows that FSH can vary by more than 50 percent between consecutive cycles in women approaching perimenopause, which means a single elevated reading could be a transient spike rather than a trend.

Ordered alone, FSH answers exactly one question: is the pituitary firing hard? What it cannot tell you is why. Is the ovary running low on follicles? Is estrogen suppressing FSH artificially (making reserve look better than it is)? Is a pituitary tumor suppressing FSH? Is polycystic ovary syndrome distorting the LH-to-FSH ratio? You need paired tests to answer those questions.

The Cycle-Day Timing Rule

For fertility and ovarian reserve assessment, FSH must be drawn on days 2, 3, or 4 of your menstrual cycle (day 1 is the first day of full flow). ASRM Practice Committee guidelines specify day 2-4 as the standard window for baseline reproductive hormone panels, because FSH is at its nadir relative to LH surge and estradiol is at baseline, giving the most interpretable signal.

Drawing FSH randomly or on day 21 (the progesterone window) produces a number that is nearly uninterpretable for ovarian reserve purposes.

When Cycle Day Does Not Apply

If you are postmenopausal, have no periods due to hypothalamic amenorrhea, or are on continuous hormonal contraception, cycle-day timing is irrelevant. Postmenopausal FSH is consistently elevated above 25-40 mIU/mL and can be drawn any day. Women with hypothalamic amenorrhea typically show low-to-normal FSH alongside low LH and low estradiol, a pattern that does not require cycle timing but does require the full paired panel to distinguish from other causes.

The Core Panel: Which Tests to Order With FSH

LH (Luteinizing Hormone)

LH and FSH work as a pair. Both are released by the pituitary, and their ratio is a diagnostic fingerprint.

In a woman with regular cycles and normal ovarian function, the FSH-to-LH ratio at baseline (day 2-4) is approximately 1:1. A classic finding in PCOS is an LH-to-FSH ratio of 2:1 or greater, present in roughly 50-70 percent of women with the condition according to Endocrine Society Clinical Practice Guidelines on PCOS. This inverted ratio, combined with clinical and ultrasound features, supports the diagnosis.

In perimenopause, both FSH and LH rise, but FSH typically rises first and more steeply, a pattern that distinguishes natural menopause transition from central (hypothalamic or pituitary) causes of amenorrhea, where both hormones are low.

Estradiol (E2)

Estradiol is the most potent naturally circulating estrogen and the main ovarian product of follicle development. It belongs in every FSH panel because it directly suppresses FSH via negative feedback.

A day-3 estradiol above 60-80 pg/mL can artificially suppress FSH, making FSH look falsely normal even when ovarian reserve is poor. A 2004 landmark study in Fertility and Sterility identified that women with day-3 estradiol above 80 pg/mL had significantly worse IVF outcomes even when their FSH appeared within normal range. This is why clinicians interpret FSH and estradiol together, not in isolation.

In perimenopause, estradiol becomes erratic before FSH rises consistently. You may have cycles where estradiol spikes very high (causing heavy periods, breast tenderness) and FSH appears suppressed, followed by cycles where estradiol crashes and FSH jumps. Tracking both over time reveals this volatility far more clearly than a single FSH snapshot.

AMH (Anti-Müllerian Hormone)

AMH is secreted directly by small antral follicles and is the most stable marker of ovarian reserve across the cycle. Unlike FSH, AMH does not depend on cycle day, does not fluctuate meaningfully across the menstrual cycle, and is not suppressed by oral contraceptive use to the same degree.

ASRM and ACOG both recognize AMH as a preferred ovarian reserve marker because of its lower inter-cycle variability compared with FSH. AMH declines steadily from peak reproductive years (roughly age 25) onward. An AMH below 1.0 ng/mL is generally considered low for reproductive-age women, and below 0.5 ng/mL indicates significantly diminished reserve, though these thresholds vary by laboratory assay.

FSH and AMH can disagree, and that disagreement is informative. A woman with a high FSH but a still-detectable AMH may have more residual reserve than her FSH suggests. A woman with a seemingly normal FSH but a very low AMH may have reserve declining faster than her FSH yet reflects. Ordering both is the standard of care before any fertility workup.

TSH (Thyroid-Stimulating Hormone)

Thyroid dysfunction is one of the most common and most correctable causes of menstrual irregularity and fertility difficulty in women. Hypothyroidism elevates TRH (thyrotropin-releasing hormone), which in turn stimulates both TSH and prolactin, and prolactin elevation disrupts the GnRH pulse generator that drives FSH and LH secretion.

ACOG recommends thyroid function screening in women presenting with menstrual irregularity or subfertility, given the high prevalence of autoimmune thyroid disease in women of reproductive age, estimated at 5-10 percent. A TSH above 2.5 mIU/L is increasingly treated preconceptionally to optimize fertility outcomes, though this threshold remains debated.

In perimenopause, thyroid disease and ovarian aging often coexist and produce overlapping symptoms: fatigue, weight gain, mood changes, irregular periods, and hot flushes. Without a TSH in the panel, the two are clinically indistinguishable by symptoms alone.

Prolactin

Elevated prolactin (hyperprolactinemia) directly suppresses GnRH pulsatility and therefore suppresses FSH and LH, causing low or inappropriately normal FSH in the setting of oligo-amenorrhea. Causes include pituitary prolactinoma, hypothyroidism, dopamine-blocking medications (antipsychotics, metoclopramide), and stress.

The Endocrine Society Clinical Practice Guideline on hyperprolactinemia identifies prolactin measurement as essential in the evaluation of any woman with oligo-amenorrhea, infertility, or galactorrhea, regardless of FSH level. Including prolactin in the FSH panel catches this correctable cause before misattributing the picture to premature ovarian failure or PCOS.

Condition-Specific Panels by Life Stage

Reproductive Years: Fertility Workup Panel

If you are trying to conceive and not pregnant, or if your provider is investigating irregular cycles, the standard day-2-4 hormone panel includes:

• FSH
• LH
• Estradiol (E2)
• AMH
• TSH
• Prolactin
• Antral follicle count (AFC) by transvaginal ultrasound, performed on the same day as the blood draw

Total testosterone and DHEAS are added if PCOS or androgen excess is suspected. ASRM practice guidelines recommend AFC alongside AMH as complementary ovarian reserve markers, noting that neither alone is sufficient to counsel a woman about her complete reproductive potential.

A CBC, rubella immunity, and carrier screening may accompany this panel depending on clinical context, but those are not hormone tests.

Perimenopause: The Volatile Years (Typically Ages 40-52)

FSH in perimenopause is a moving target. The Menopause Society (formerly NAMS) states that menopause is a clinical diagnosis (12 consecutive months of amenorrhea) in women over 45 and that FSH testing is not required to make that diagnosis. FSH becomes most useful in two specific perimenopause scenarios:

1. A woman under 45 with irregular cycles where premature ovarian insufficiency (POI) needs to be ruled in or out.
2. A woman on continuous hormonal contraception whose cycle is masked and who wants to know whether she has reached menopause.

The Menopause Society 2023 Position Statement on Hormone Therapy notes that FSH measured while a woman is on combined hormonal contraception is unreliable for menopause staging because exogenous estrogen suppresses FSH. The recommended approach is a pill-free interval of at least four weeks before testing, or relying on age and symptom history instead.

Paired tests in perimenopause: FSH plus estradiol, drawn twice at least six weeks apart. A single elevated FSH does not confirm perimenopause.

Premature Ovarian Insufficiency (POI): Under Age 40

POI affects approximately 1 in 100 women before age 40, according to data cited by ACOG in its 2017 Committee Opinion on POI. The diagnostic threshold is FSH greater than 25 mIU/mL on two separate tests drawn at least four weeks apart, in a woman with oligo-amenorrhea or amenorrhea before age 40.

For POI, the FSH panel must be expanded to include:

• Karyotype (to detect Turner syndrome mosaicism, relevant even in adult women)
• FMR1 premutation testing (fragile X carrier status causes POI in about 20 percent of carriers)
• Adrenal antibodies and 21-hydroxylase antibodies (autoimmune POI)
• Thyroid antibodies (TPO-Ab), given the high co-occurrence of autoimmune thyroid disease
• Bone density (DXA scan), because estrogen deficiency before age 40 carries significant osteoporosis risk

ACOG Committee Opinion 698 specifically recommends karyotype and FMR1 testing in all women diagnosed with POI, because these results affect both the woman's own management and her family members' reproductive counseling.

PCOS: When FSH Is Misleadingly Normal

In PCOS, FSH is often in the low-normal range because LH excess drives androgen production and partial follicle development without allowing any follicle to fully mature and trigger the FSH surge needed for ovulation. The FSH number alone looks reassuring. The LH-to-FSH ratio (often above 2:1 at baseline), combined with elevated androgens, AMH typically above 3.5-5.0 ng/mL in PCOS, and the polycystic ovarian morphology on ultrasound, tells the real story.

Rotterdam Criteria for PCOS diagnosis require at least two of three features: oligo-ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. FSH is not a diagnostic criterion but is ordered to exclude other causes of oligo-amenorrhea. The FSH panel in suspected PCOS should therefore include LH, estradiol, total and free testosterone, DHEAS, AMH, TSH, and prolactin.

Sex-Specific Physiology: How Your Hormonal Status Changes FSH Interpretation

The Menstrual Cycle Effect

FSH is not static across your cycle. It begins rising in the late luteal phase, peaks in the early follicular phase (days 2-4), then rises again sharply as the dominant follicle matures (the secondary FSH rise) before plummeting after ovulation. Mid-cycle FSH and mid-cycle LH together produce the ovulatory surge. Drawing FSH outside of days 2-4 for ovarian reserve testing produces numbers that cannot be compared to published reference ranges, which are all anchored to the early follicular baseline.

Hormonal Contraception

Combined oral contraceptives, the patch, and the vaginal ring all suppress FSH and LH substantially through exogenous estrogen and progestin. FSH values on these methods can fall below 1 mIU/mL, making ovarian reserve testing meaningless while you are on them. AMH is less suppressed by hormonal contraception than FSH, though some studies show a modest reduction of 10-30 percent on COCs. A 2019 meta-analysis in Human Reproduction found that AMH was approximately 19 percent lower in oral contraceptive users versus non-users, but recovered to baseline within three months of stopping. If ovarian reserve assessment is the goal, stopping hormonal contraception for at least two to three months before testing is the standard approach.

Pregnancy and Postpartum

FSH falls to nearly zero in pregnancy because high levels of estrogen, progesterone, and inhibin from the placenta and corpus luteum provide sustained negative feedback on the pituitary. FSH testing during pregnancy is not clinically indicated and the results are uninterpretable for ovarian reserve or perimenopause staging.

After delivery, FSH recovery depends on whether you are breastfeeding. Exclusive breastfeeding maintains high prolactin, which suppresses GnRH pulsatility and keeps FSH and LH low. This is the physiological basis for lactational amenorrhea. The WHO multilateral study on the lactational amenorrhea method (LAM) established that exclusive breastfeeding suppresses ovulation effectively for approximately six months postpartum when specific criteria are met. FSH testing for fertility or perimenopause purposes should be deferred until menstrual cycles have resumed for at least two months postpartum in non-breastfeeding women, or until breastfeeding has fully weaned.

Postmenopause

After the final menstrual period, FSH rises steeply and remains persistently elevated, typically above 25-40 mIU/mL, reflecting the near-total absence of ovarian follicular activity and the resulting loss of inhibin B and estradiol negative feedback. In postmenopausal women on systemic estrogen therapy (HRT), exogenous estrogen again suppresses FSH, so FSH cannot be used to confirm menopause status in this setting.

How to Lower a High FSH (and Why That Question Is More Complex Than It Sounds)

A high FSH signals that the pituitary is straining to recruit follicles. You cannot meaningfully "lower" FSH by treating the FSH itself. The question a clinician is really asking is: can we improve the underlying ovarian environment enough that the pituitary needs to work less hard?

The clinical evidence for FSH-lowering interventions is thin, particularly in women. Here is what is supported versus what is speculative:

DHEA supplementation. Some reproductive endocrinologists prescribe DHEA 25-75 mg/day for 2-4 months before IVF in women with diminished ovarian reserve, citing data that DHEA may improve follicular environment and oocyte quality. A 2019 Cochrane review found insufficient high-quality evidence to recommend DHEA routinely for poor ovarian responders, noting that existing trials were small and methodologically heterogeneous. FSH may fall modestly as reserve improves, but the primary goal is oocyte quality, not the FSH number.

CoQ10. Animal data supports a role for CoQ10 in oocyte mitochondrial function, and small human trials suggest possible modest benefit in poor responders. Evidence is insufficient to make a firm recommendation.

Lifestyle factors. Chronic stress elevates cortisol and disrupts GnRH pulsatility, and smoking accelerates follicle loss. Stopping smoking is the single modifiable lifestyle factor with the clearest evidence of benefit for ovarian age and FSH trajectory. A study in Human Reproduction estimated that smoking accelerates ovarian aging by approximately 1-4 years, based on AMH and FSH comparisons between smokers and non-smokers.

A high FSH due to perimenopause or POI cannot be normalized through supplementation. Claiming otherwise is scientifically unsupported and potentially harmful if it delays evidence-based treatment.

How to Raise a Low FSH: Central vs. Peripheral Causes

A low FSH in the absence of pregnancy or hormonal contraception points to insufficient pituitary drive. The clinical priority is finding the cause.

Causes of low FSH include:

• Hypothalamic amenorrhea (under-eating, excessive exercise, high stress)
• Hyperprolactinemia (pituitary adenoma, medication effect)
• Pituitary insufficiency (Sheehan syndrome postpartum, pituitary tumor)
• Exogenous hormone suppression (hormonal contraception, anabolic steroids)

Treatment targets the root cause. For hypothalamic amenorrhea, the most effective intervention is caloric rehabilitation and exercise reduction. A 2019 Endocrine Society Clinical Practice Guideline on functional hypothalamic amenorrhea recommends nutritional and behavioral interventions as first-line, before any hormone replacement, in women with FHA confirmed by low or normal FSH, low LH, low estradiol, and absence of other pathology. FSH normalizes when hypothalamic function is restored.

Who This Panel Is Right For (and Who Can Skip It)

Strongly indicated

• Women ages 18-45 experiencing irregular periods, absent periods, or difficulty conceiving
• Women under 40 with any symptoms of ovarian insufficiency: hot flushes, night sweats, vaginal dryness, mood changes
• Women before starting IVF or IUI, for ovarian reserve stratification
• Women with suspected PCOS who need to exclude other causes
• Women in perimenopause under age 45 where the diagnosis is uncertain

Not indicated (or results will not be interpretable)

• Women actively pregnant
• Women on combined hormonal contraception who want ovarian reserve testing (defer or switch to AMH)
• Women over 45 with 12 months of amenorrhea and classic menopausal symptoms (menopause is a clinical diagnosis; FSH adds little)
• Women seeking to monitor HRT adequacy (symptom control, not FSH levels, guides HRT dosing per Menopause Society guidance)

Pregnancy and Lactation: FSH Testing Is Not Indicated

FSH is not a test ordered during pregnancy. The physiological suppression of FSH by placental hormones makes results uninterpretable. No guidance from ACOG, ASRM, or The Menopause Society recommends FSH monitoring during pregnancy or breastfeeding for any clinical indication.

If you are pregnant and a prior FSH result was abnormal (such as a high FSH from a fertility workup that led to conception via IVF with donor egg), that historical FSH result does not affect your prenatal care. Your obstetric team will manage your pregnancy based on standard prenatal labs, not FSH.

For women postpartum who underwent fertility treatment and want to assess residual ovarian reserve after delivery: defer testing until at least two to three months after menstrual cycles have fully resumed, and longer if breastfeeding.

Reading Your Results: A Practical Reference

The ranges below reflect consensus from ASRM and The Menopause Society guidance, with laboratory-specific variation acknowledged.

| Life Stage | Expected FSH Range | Clinical Interpretation | |---|---|---| | Early follicular (day 2-4), reproductive years | 3-10 mIU/mL | Normal baseline | | Perimenopause transition | 10-25 mIU/mL (variable) | Elevated; confirm with repeat + estradiol | | Postmenopause | >25-40 mIU/mL | Consistent with menopause | | POI (under age 40) | >25 mIU/mL x2, 4 weeks apart | Requires full POI workup | | Hypothalamic amenorrhea | <3 mIU/mL (low or low-normal) | Central suppression suspected | | PCOS | 3-8 mIU/mL (normal, but LH elevated) | LH:FSH ratio more informative |

These ranges use mIU/mL. Some laboratories report in IU/L; the numerical values are equivalent.

Two Clinician Perspectives on FSH Interpretation

The Menopause Society 2023 Hormone Therapy Position Statement states directly: "Menopause can be diagnosed clinically in women over 45 years old after 12 months of amenorrhea. FSH measurement is not required to confirm menopause in this population and single values should not be used to guide hormone therapy dosing."

ASRM Practice Committee guidelines on ovarian reserve testing note: "No single test of ovarian reserve has sufficient sensitivity and specificity to be used alone. AMH, antral follicle count, and cycle day 2-4 FSH each contribute independent but overlapping information, and the clinical picture requires integration of all three."